Skip to content

Zymeworks ZYME Deferred Foreign Income Tax Expense Benefit

Deferred Foreign Income Tax Expense Benefit at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$234.5K+95.4%
Charles River Laboratories logo
Charles River LaboratoriesCRL
-$5.6M-224%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
-$257K-137%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:DeferredForeignIncomeTaxExpenseBenefit.

The official record: Zymeworks’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's deferred foreign income tax expense benefit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's deferred foreign income tax expense benefit?
Zymeworks (ZYME) reported deferred foreign income tax expense benefit of $25K in Q4 2025.
What does deferred foreign income tax expense benefit mean?
Represents the change in deferred tax assets or liabilities resulting from temporary differences between the financial reporting and tax bases of assets and liabilities in foreign jurisdictions. This metric helps investors understand the impact of foreign tax timing differences on future cash tax obligations.